Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 3/20 | 0.58 |
| ▸ | BMPR1A | P36894 | 3/20 | 0.58 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.58 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.58 |
| ▸ | MERTK | Q12866 | 15/20 | 0.56 |
| ▸ | AXL | P30530 | 14/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.51 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.51 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21460284 | 0.98 | BMPR1B (0.61) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL20067672 | 0.92 | BMPR1B (0.57) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL20067643 | 0.92 | BMPR1B (0.57) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL20067644 | 0.91 | BMPR1B (0.61) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21460287 | 0.89 | BMPR1B (0.56) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21460213 | 0.89 | AXL (0.60) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21473948 | 0.88 | IKBKE (0.54) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21473934 | 0.88 | BMPR1B (0.53) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21460279 | 0.88 | BMPR1B (0.63) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21460290 | 0.88 | BMPR1B (0.57) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | disclosed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | disclosed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | disclosed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | disclosed |
| WO-2018071343-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB4 | BMPR1B 1108/4885BMPR1A 1011/4885ACVRL1 718/4885 |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB4 | BMPR1B 1108/4885BMPR1A 1011/4885ACVRL1 718/4885 |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB2 | BMPR1B 817/4885BMPR1A 736/4885ACVRL1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.